Anixa Biosciences, Inc.ANIXNASDAQ
Loading
R&D Expenses Over TimeStable
Percentile Rank53
3Y CAGR-1.0%
5Y CAGR-5.7%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
-1.0%/yr
vs -3.4%/yr prior
5Y CAGR
-5.7%/yr
Recent acceleration
Acceleration
+2.3pp
Accelerating
Percentile
P53
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
2 yr
Consecutive declineStable
PeriodValueYoY Change
TTM$4.62M-8.9%
2025$5.07M-20.7%
2024$6.40M+34.1%
2023$4.77M-28.9%
2022$6.70M+8.3%
2021$6.19M+41.3%
2020$4.38M-20.0%
2019$5.47M-19.7%
2018$6.81M+326.5%
2017$1.60M-